SOLUBLE SERUM CD163 (SCD163) LEVELS IS A MARKER OF DISEASE ACTIVITY IN LYMPHOPLASMACYTIC LYMPHOMA (LPL). PRELIMINARY RESULTS

Abstract

Introduction: sCD163 is secreted by monocyte-macrophage lineage cells, including Tumor-Αssociated Μacrophages (TAM) that participate in neoplastic and immune regulation. LPL is a lymphoproliferative neoplastic disorder, the spectrum of which comprises Waldenstrom’s macroglobulinaemia (WM) in its symptomatic, asymptomatic and precursor forms as well as non-secreting or IgG/IgA-secreting cases. sCD163 eventual role in LPL has not been investigated so far. Aims: To determine sCD163 levels in a series of LPL patients at diagnosis and evaluate possible correlations with disease activity. Patients and Methods: Twenty-nine patients were studied (24 WM of whose 5 asymptomatic, 2 IgM-MGUS with related peripheral neuropathy and 3 LPL) after their informed consent. Clinical and routine laboratory data were collected. Median time to treatment (TTT) was 11 months and median overall survival (OS) 128 months. Serum sCD163 was tested in frozen sera of patients collected at diagnosis and in 15 healthy individuals (HI). Measurements were performed by ELISA (Duo-Set R&D Quantiquine) according to the manufacturer’s instructions. Statistical analysis was performed with the SPSS v.26 software and survival curves were drawn by the Kaplan-Mayer methods and compared by the log-rank test. Results: Median serum sCD163 was 109000 pg/mL and 117952 pg/mL in patients and HI respectively. Time to treatment was significantly shorter in patients with serum sCD163 values above median (p = 0.004), compared to the others (figure). In addition sCD163 levels were correlated with platelet number, the presence of lymphadenopathy and IgM in WM-only patients. Keywords: diagnostic and prognostic biomarkers, indolent non-Hodgkin lymphoma, tumor biology and heterogeneity No conflicts of interests pertinent to the abstract.